PRLD

Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.

Wall Street analysts forecast PRLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Prelude Therapeutics Inc revenue for the last quarter amounts to 6.50M USD, increased 116.67 % YoY.

Prelude Therapeutics Inc. EPS for the last quarter amounts to -0.26 USD, decreased -39.53 % YoY.

Prelude Therapeutics Inc (PRLD) has 131 emplpoyees as of December 15 2025.

Today PRLD has the market capitalization of 107.50M USD.